Actinium Pharma (ATNM) –
-
Actinium Pharma (ATNM) Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
-
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
-
Actinium Pharma (ATNM) Launches Actinium-225 Focused Strategic Initiative
-
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
-
Actinium Pharma (ATNM) Reports Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML
-
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transpla
-
Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B
-
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transp
-
Form SC 13G/A Actinium Pharmaceuticals Filed by: Bigger Capital, LLC
-
Form EFFECT Actinium Pharmaceuticals
-
Actinium Pharma (ATNM) Files $500M Mixed Shelf
-
Form S-3/A Actinium Pharmaceuticals
-
Form SC 13G Actinium Pharmaceuticals Filed by: BlackRock Inc.
-
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
-
Form 4 Actinium Pharmaceuticals For: Dec 28 Filed by: Nicholson, C. David
-
Form 4 Actinium Pharmaceuticals For: Dec 28 Filed by: Steinhart Richard I
-
Form 4 Actinium Pharmaceuticals For: Dec 28 Filed by: O'Loughlin Steve
-
Form 4 Actinium Pharmaceuticals For: Dec 28 Filed by: Shetty Ajit
-
Form 4 Actinium Pharmaceuticals For: Dec 28 Filed by: SETH SANDESH
-
Form 4 Actinium Pharmaceuticals For: Dec 28 Filed by: Chell Jeffrey W.
-
Actinium (ATNM) Announces Iomab-B Produces High Response Rates and Significant Improvement in OS in R/R AML Patients with Active Disease Overcoming TP53 Mutation
-
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
-
Actinium Pharma (ATNM) PT Lowered to $16 at B.Riley
-
Actinium Pharma (ATNM) Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with R/R AML
-
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
-
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Expos
-
Form 8-K Actinium Pharmaceuticals For: Nov 30
-
Form ARS Actinium Pharmaceuticals For: Dec 31
-
Form DEF 14A Actinium Pharmaceuticals For: Nov 30
-
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
-
Actinium Pharma (ATNM) Appoints Lynn Bodarky as Chief Business Officer
-
Actinium Appoints Lynn Bodarky as Chief Business Officer
-
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
-
Form 10-Q Actinium Pharmaceuticals For: Sep 30
-
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable
-
Actinium Pharma (ATNM) Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
-
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
-
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
-
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
-
Amgen and Biogen 'look attractive' - HSBC
-
HSBC Starts Actinium Pharma (ATNM) at Buy
-
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
-
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
-
Actinium Pharma (ATNM) PT Lowered to $50 at H.C. Wainwright
-
Form 10-Q Actinium Pharmaceuticals For: Jun 30
-
Actinium Pharma (ATNM) Files $500M Mixed Shelf
-
Form S-3 Actinium Pharmaceuticals
-
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
-
SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data
-
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting
Back to ATNM Stock Lookup